title: Vagus nerve stimulation in pediatric epilepsy: a review.
abstract: Therapeutic options for intractable epilepsy include new and investigational antiepileptic drugs, ketogenic diet, epilepsy surgery, and, now, vagus nerve stimulation, which is approved by the U.S. Food and Drug Administration for the treatment of refractory partial seizures in adolescents and adults. The exact mechanisms of action are unknown. Although the use of vagus nerve stimulation in children has increased, including those younger than 12 years of age or those with generalized epilepsy, there has been no large controlled pediatric study to date. The identification of favorable prognostic indicators, especially in children, would be useful. Preliminary results suggest that children with Lennox-Gastaut syndrome may have a favorable response, with improvement in both seizure control and global evaluation scores. Improved global evaluation scores have occurred even without an associated improvement in seizure control.
authors.affiliation: Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Children's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: I
authors.initials: I
authors.lastname: Valencia
authors.forename: D L
authors.initials: DL
authors.lastname: Holder
authors.forename: S L
authors.initials: SL
authors.lastname: Helmers
authors.forename: J R
authors.initials: JR
authors.lastname: Madsen
authors.forename: J J
authors.initials: JJ
authors.lastname: Riviello
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D018795:Device Approval; D004599:Electric Stimulation Therapy / Q000295:instrumentation*; D004827:Epilepsy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D019736:Prostheses and Implants; D016896:Treatment Outcome; D014630:Vagus Nerve / Q000503:physiopathology*